Defence Therapeutics (DTC) Ownership - Who Owns Defence Therapeutics?
Defence Therapeutics (DTC) Ownership Overview
- 9.98% Insiders
- 90.02% Public Companies and Individual Investors
The ownership structure of Defence Therapeutics (DE:DTC) stock is a mix of institutional, retail, and individual investors. , 9.98% is owned by Insiders, and 90.02% is owned by Public Companies and Individual Investors.
The ownership structure of Defence Therapeutics (DE:DTC) stock is a mix of institutional, retail, and individual investors. , 9.98% is owned by Insiders, and 90.02% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Oct 23, 2026 | Amie Lynn Lambermon-phinney | C$6,268 | |
| Mar 27, 2026 | Omar Rifai | C$2,750,000 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Omar Rifai | 5,750,000 | Insider | 7.59% | 1,472,000 |
| Sébastien Plouffe | 1,800,000 | Insider | 2.38% | 460,800 |
| Amie Lynn Lambermon-phinney | 16,333 | Insider | 0.02% | 4,181 |
FAQ
What percentage of Defence Therapeutics (DE:DTC) stock is held by retail investors?
According to the latest TipRanks data, approximately 90.02% of Defence Therapeutics (DE:DTC) stock is held by public companies and individual investors.
Who owns the most shares of Defence Therapeutics (DE:DTC)?
Omar Rifai owns the most shares of Defence Therapeutics (DE:DTC).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
